Buscar
MoonLake Immunotherapeutics
MLTXAñadir a la lista de seguimiento
19.110USD
-0.021-0.11%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.36BCap. mercado
PérdidaP/E TTM
Más Datos de MoonLake Immunotherapeutics Compañía
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Información de MoonLake Immunotherapeutics
Símbolo de cotizaciónMLTX
Nombre de la empresaMoonLake Immunotherapeutics
Fecha de salida a bolsaOct 20, 2020
Director ejecutivoSantos Da Silva (Jorge)
Número de empleados100
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 20
DirecciónDorfstrasse 29
CiudadZUG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal6300
Teléfono41415108022
Sitio Webhttps://moonlaketx.com/
Símbolo de cotizaciónMLTX
Fecha de salida a bolsaOct 20, 2020
Director ejecutivoSantos Da Silva (Jorge)
Ejecutivos de MoonLake Immunotherapeutics
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de MoonLake Immunotherapeutics?
Los cinco principales accionistas de MoonLake Immunotherapeutics son: Dr. Kristian Reich
¿Cuántas instituciones poseen acciones de MoonLake Immunotherapeutics (MLTX)?
A fecha de 2026Q1, 358 instituciones poseen acciones de MoonLake Immunotherapeutics, con un valor de mercado combinado de aproximadamente 54.44M, lo que representa el 74.73% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3151979.00.